• Je něco špatně v tomto záznamu ?

Analysis of incidence and prevalence of cardiovascular risk factors and evaluation of their control in epidemiological survey in the Czech Republic

Z. Chmelík, M. Vaclová, V. Lánská, J. Laštůvka, M. Vrablík

. 2020 ; 28 (2) : 114-119.

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20010303

Digitální knihovna NLK
Zdroj

E-zdroje Online Plný text

NLK Free Medical Journals od 2004
ProQuest Central od 2009-03-01 do Před 6 měsíci
Medline Complete (EBSCOhost) od 2006-03-01 do Před 6 měsíci
Nursing & Allied Health Database (ProQuest) od 2009-03-01 do Před 6 měsíci
Health & Medicine (ProQuest) od 2009-03-01 do Před 6 měsíci
Public Health Database (ProQuest) od 2009-03-01 do Před 6 měsíci
ROAD: Directory of Open Access Scholarly Resources od 1993

OBJECTIVE: The aim of this analysis was to analyze the presence of the most important cardiovascular (CV) risk factors and to discuss patterns of LDL cholesterol management in the population studied. METHODS: We enrolled 961 males, average age of 42.9 ± 4.7, and 851 females, average age of 51.2 ± 3.6. Data on personal, pharmacological and family history, and laboratory examinations were collected. Cardiovascular (CV) risk was calculated using the Systematic Coronary Risk Evaluation (SCORE) algorithm with modifications according to the guidelines. RESULTS: The distribution of CV risk in the observed cohort was as follows: 24% of the subjects had low, 51% moderate, 17% high and 8% very high risk. The percentage of patients who reached target values of LDL cholesterol was dramatically lower in the groups with very high (1%) and high (3%) risk than in the groups with moderate (14%) or low risk (59%). Dyslipidemia was newly identified in 20% of both sexes. Arterial hypertension was newly diagnosed in 8% of males and 5% of females, and type 2 diabetes mellitus was newly diagnosed in 3% of both the males and females. Dyslipidemia was present in 39% of males and 41% of females; arterial hypertension in 43% of males and 45% of females, and type 2 diabetes mellitus was diagnosed in 11% of the subjects of both sexes. 49% of males and 31% of females were overweight and 32% of both genders were obese. There were 36% of male smokers and 22% of female smokers. 48% of the participants were pharmacologically treated. Non-pharmacological treatment was recommended to 62% of male and to 65% of female participants. Pharmacological intervention was started in 53% of males and 51% of females. In both gender antihypertensive treatment with angiotensin-converting enzyme (ACE) inhibitors (29% of males and 27% of females) and lipid lowering therapy with a statin (28% of males, 27% of females) were the most commonly initiated treatments. In the subgroup of the 101 patients with LDL cholesterol levels > 5 mmol/L 56% were not treated with a statin. The analysis of relationship between the positive family history of any of the followed CV risks showed significant increases of the risk for arterial hypertension, type 2 diabetes mellitus and dyslipidemia. CONCLUSION: European guidelines suggest general screening for risk factors, including analysis of lipid profiles in the population of 40-year-old males and 50-year-old or postmenopausal women. Our study documents high prevalence and incidence of CV risk factors together with insufficient control of the risk factors in Czech patients of this age range. This finding suggests that preventive examinations should be undertaken earlier (e.g., in 30-year-old males and 40-year-old women). Exact timing of the preventive check-ups to yield the best cost-benefit ratio needs to be verified.

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc20010303
003      
CZ-PrNML
005      
20200721124455.0
007      
ta
008      
200707s2020 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.21101/cejph.a5730 $2 doi
035    __
$a (PubMed)32592555
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Chmelík, Zdeněk $7 xx0224754 $u Third Department of Internal Medicine, Department of Endocrinology, Metabolism, First Medical Faculty, Charles University, General Faculty Hospital, Prague, Czech Republic
245    10
$a Analysis of incidence and prevalence of cardiovascular risk factors and evaluation of their control in epidemiological survey in the Czech Republic / $c Z. Chmelík, M. Vaclová, V. Lánská, J. Laštůvka, M. Vrablík
504    __
$a Literatura
520    9_
$a OBJECTIVE: The aim of this analysis was to analyze the presence of the most important cardiovascular (CV) risk factors and to discuss patterns of LDL cholesterol management in the population studied. METHODS: We enrolled 961 males, average age of 42.9 ± 4.7, and 851 females, average age of 51.2 ± 3.6. Data on personal, pharmacological and family history, and laboratory examinations were collected. Cardiovascular (CV) risk was calculated using the Systematic Coronary Risk Evaluation (SCORE) algorithm with modifications according to the guidelines. RESULTS: The distribution of CV risk in the observed cohort was as follows: 24% of the subjects had low, 51% moderate, 17% high and 8% very high risk. The percentage of patients who reached target values of LDL cholesterol was dramatically lower in the groups with very high (1%) and high (3%) risk than in the groups with moderate (14%) or low risk (59%). Dyslipidemia was newly identified in 20% of both sexes. Arterial hypertension was newly diagnosed in 8% of males and 5% of females, and type 2 diabetes mellitus was newly diagnosed in 3% of both the males and females. Dyslipidemia was present in 39% of males and 41% of females; arterial hypertension in 43% of males and 45% of females, and type 2 diabetes mellitus was diagnosed in 11% of the subjects of both sexes. 49% of males and 31% of females were overweight and 32% of both genders were obese. There were 36% of male smokers and 22% of female smokers. 48% of the participants were pharmacologically treated. Non-pharmacological treatment was recommended to 62% of male and to 65% of female participants. Pharmacological intervention was started in 53% of males and 51% of females. In both gender antihypertensive treatment with angiotensin-converting enzyme (ACE) inhibitors (29% of males and 27% of females) and lipid lowering therapy with a statin (28% of males, 27% of females) were the most commonly initiated treatments. In the subgroup of the 101 patients with LDL cholesterol levels > 5 mmol/L 56% were not treated with a statin. The analysis of relationship between the positive family history of any of the followed CV risks showed significant increases of the risk for arterial hypertension, type 2 diabetes mellitus and dyslipidemia. CONCLUSION: European guidelines suggest general screening for risk factors, including analysis of lipid profiles in the population of 40-year-old males and 50-year-old or postmenopausal women. Our study documents high prevalence and incidence of CV risk factors together with insufficient control of the risk factors in Czech patients of this age range. This finding suggests that preventive examinations should be undertaken earlier (e.g., in 30-year-old males and 40-year-old women). Exact timing of the preventive check-ups to yield the best cost-benefit ratio needs to be verified.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a inhibitory ACE $x terapeutické užití $7 D000806
650    _2
$a antihypertenziva $x terapeutické užití $7 D000959
650    _2
$a kardiovaskulární nemoci $x farmakoterapie $x epidemiologie $7 D002318
650    _2
$a diabetes mellitus 2. typu $x farmakoterapie $x epidemiologie $7 D003924
650    _2
$a dyslipidemie $x farmakoterapie $x epidemiologie $7 D050171
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a statiny $x terapeutické užití $7 D019161
650    _2
$a hypertenze $x farmakoterapie $x epidemiologie $7 D006973
650    _2
$a incidence $7 D015994
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a obezita $x farmakoterapie $x epidemiologie $7 D009765
650    _2
$a prevalence $7 D015995
650    _2
$a rizikové faktory $7 D012307
650    _2
$a průzkumy a dotazníky $7 D011795
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vaclová, Martina $7 xx0160828 $u Third Department of Internal Medicine, Department of Endocrinology, Metabolism, First Medical Faculty, Charles University, General Faculty Hospital, Prague, Czech Republic
700    1_
$a Lánská, Věra $7 xx0062305 $u Department of Hygiene, Institute of Clinical, Experimental Medicine, Prague, Czech Republic
700    1_
$a Laštůvka, Jiří, $d 1968- $7 xx0242090 $u Third Department of Internal Medicine, Department of Endocrinology, Metabolism, First Medical Faculty, Charles University, General Faculty Hospital, Prague, Czech Republic; Internal Department, Masaryk Hospital, Usti nad Labem, Czech Republic
700    1_
$a Vrablík, Michal, $d 1973- $7 xx0061419 $u Third Department of Internal Medicine, Department of Endocrinology, Metabolism, First Medical Faculty, Charles University, General Faculty Hospital, Prague, Czech Republic
773    0_
$w MED00001083 $t Central European journal of public health $x 1210-7778 $g Roč. 28, č. 2 (2020), s. 114-119
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32592555 $y Pubmed
910    __
$a ABA008 $b B 1829 $c 562 $y p $z 0
990    __
$a 20200707 $b ABA008
991    __
$a 20200710152052 $b ABA008
999    __
$a ok $b bmc $g 1546298 $s 1100395
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 28 $c 2 $d 114-119 $i 1210-7778 $m Central European Journal of Public Health $n Cent. Eur. J. Public Health $x MED00001083
LZP    __
$b NLK118 $a Pubmed-20200707

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...